




**Believe what you see**

# Overview

- **Dobecure, s.l.** we are a biomedical investigation company, aimed to develop different therapies based in the use of **synthetic inhibitors of fibroblast growth factor (FGF)**, for diseases associated with inflammation and angiogenesis.
- In **Dobecure** we focus our research activity in **ophthalmology diseases** (age-related macular degeneration, both wet and dry, uveitis, corneal edema and herpetic queratitis). We are also **exploring other research fields** such as tendinitis and tendinosis, cold sores, otitis and allergic rhinitis, and some rare diseases.
- Headquartered in Madrid – Spain, **Dobecure** is a private entity, opened to any investment that shares its objectives and values, mainly referred to the **medical investigation**.



# Objectives



- **Investigate to cure.**
- Provide an effective and safe treatment for those diseases that can be treated with **inhibitors of fibroblast growth factor (anti-FGF)** particularly in the inflammation and angiogenesis processes.
- **Out-licence** those inhibitors and the clinical results for a better distribution in the global market, while contributing to treat diseases associated with inflammation and angiogenesis which prevalence affects more than 500 million people worldwide.
- Continue investigating in new potential clinical uses for the **synthetic inhibitors of fibroblast growth factor (FGF)**

# Begginings

**Dobecure** arises in summer 2017 as a tool to lead to the market the investigation developed all over the years from its scientific board members with the **FGF inhibitors**.




Based on the preclinical and clinical investigations, developed since the late 80's, it has been developed the **registration dossier of the FGF inhibitors for the treatment of both presentation means (dry and wet) of age-related macular degeneration (AMD)**.

Moreover, **Dobecure** continues with the preclinical and clinical studies in other disorders where the FGF might be involved.

# Scientific Board



**Dr. Pedro Cuevas Sánchez**  
Head of Investigation  
Chair of Cardiology  
Universidad Alfonso X el Sabio



**Dr. Luis Outeiriño**  
Head of Ophtalmology Service  
Hospital Pio XII



**Prof. Guillermo Giménez Gallego**  
Research Professor  
Biological Investigations Centre  
CESIC. – Spain.



**Rocío García Cañamaque**  
Clinical Research Expert  
Funder - LeónResearch

# Management Team





**Diego Cuevas Bourdier**  
President  
Dobecure, s.l.




**Alfonso García Cañamaque**  
CEO  
Dobecure, s.l.

# Strategy



# Pipeline





# Industrial Property

- Actually we have the following international patents:
  - Patent **EP 2 777 699 A1**, for **ophthalmological use**, validated in several European countries (Spain, France, United Kingdom, Germany, Italy, Switzerland and the Confederation Helvetica, Portugal).
  - We have applied for the patent **in otitis and allergic rhinitis** with the code **EP 15380045.3** in the European Patent Office.

# Investors

- **100% of the capital** is private.
- We are preparing a report to apply for **European funds** (H2020, SME Instrument) and also for **Local funds** (ENISA, CDTI, SODICAL, MADRID+D).
- Our research focuses on those diseases which currently **do not have adequate treatments** or for which there is no approved treatment.
- We are looking for investors who want to contribute to the project **financially**, but also with **experience** that will allow us to advance in the clinical research phases and regulatory strategies to obtain the registration for the pathologies of our investigations.

# Believe what you see



[www.dobecure.com](http://www.dobecure.com)

email: [alfonso.garcia@dobecure.com](mailto:alfonso.garcia@dobecure.com)  
Tel. +34 691 49 40 49

**DobeCure** 